A cut-off serum-IL-6 level above 100 pg/ml identified 80% of the bile duct cancer patients and excluded healthy adults, all patients with benign bile disease and 92% of the hepatocellular carcinoma patients. This evidence concerns the gene IL6 and hepatocellular carcinoma.